These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 12236846)

  • 1. The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects.
    Boffito M; Hoggard PG; Reynolds HE; Bonora S; Meaden ER; Sinicco A; Di Perri G; Back DJ
    Br J Clin Pharmacol; 2002 Sep; 54(3):262-8. PubMed ID: 12236846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intracellular accumulation of human immunodeficiency virus protease inhibitors.
    Khoo SH; Hoggard PG; Williams I; Meaden ER; Newton P; Wilkins EG; Smith A; Tjia JF; Lloyd J; Jones K; Beeching N; Carey P; Peters B; Back DJ
    Antimicrob Agents Chemother; 2002 Oct; 46(10):3228-35. PubMed ID: 12234849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indinavir protein-free concentrations when used in indinavir/ritonavir combination therapy.
    King JR; Gerber JG; Fletcher CV; Bushman L; Acosta EP
    AIDS; 2005 Jul; 19(10):1059-63. PubMed ID: 15958837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations.
    Schapiro JM; Winters MA; Lawrence J; Merigan TC
    AIDS; 1999 Feb; 13(3):359-65. PubMed ID: 10199226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of alpha1-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir in vitro.
    Jones K; Hoggard PG; Khoo S; Maher B; Back DJ
    Br J Clin Pharmacol; 2001 Jan; 51(1):99-102. PubMed ID: 11167671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.
    Chetchotisakd P; Anunnatsiri S; Mootsikapun P; Kiertiburanakul S; Anekthananon T; Bowonwatanuwong C; Kowadisaiburana B; Supparatpinyo K; Ruxrungtham K;
    HIV Med; 2007 Nov; 8(8):529-35. PubMed ID: 17944686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maintenance of indinavir by dose adjustment in HIV-1-infected patients with indinavir-related toxicity.
    Wasmuth JC; Lambertz I; Voigt E; Vogel M; Hoffmann C; Burger D; Rockstroh JK
    Eur J Clin Pharmacol; 2007 Oct; 63(10):901-8. PubMed ID: 17690876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline human immunodeficiency virus type 1 phenotype, genotype, and RNA response after switching from long-term hard-capsule saquinavir to indinavir or soft-gel-capsule saquinavir in AIDS clinical trials group protocol 333.
    Para MF; Glidden DV; Coombs RW; Collier AC; Condra JH; Craig C; Bassett R; Leavitt R; Snyder S; McAuliffe V; Boucher C
    J Infect Dis; 2000 Sep; 182(3):733-43. PubMed ID: 10950766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors.
    Barreiro P; Camino N; de Mendoza C; Valer L; Núñez M; Martín-Carbonero L; González-Lahoz J; Soriano V
    Int J Antimicrob Agents; 2002 Dec; 20(6):438-43. PubMed ID: 12458138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial.
    Dragsted UB; Gerstoft J; Pedersen C; Peters B; Duran A; Obel N; Castagna A; Cahn P; Clumeck N; Bruun JN; Benetucci J; Hill A; Cassetti I; Vernazza P; Youle M; Fox Z; Lundgren JD;
    J Infect Dis; 2003 Sep; 188(5):635-42. PubMed ID: 12934178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic and intestinal contributions to pharmacokinetic interaction of indinavir with amprenavir, nelfinavir and saquinavir in rats.
    Gao W; Kishida T; Kageyama M; Kimura K; Yoshikawa Y; Shibata N; Takada K
    Antivir Chem Chemother; 2002 Jan; 13(1):17-26. PubMed ID: 12180646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Once-daily dosing of saquinavir soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 study).
    Lamotte C; Landman R; Peytavin G; Mentre F; Gerbe J; Brun-Vezinet F; Boue F; Spiridon G; Valantin MA; Michelet C; Farinotti R; Yeni P
    Antivir Ther; 2004 Apr; 9(2):247-56. PubMed ID: 15134187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of virologic, immunologic, and clinical response to five different initial protease inhibitor-containing and nevirapine-containing regimens.
    Easterbrook PJ; Newson R; Ives N; Pereira S; Moyle G; Gazzard BG
    J Acquir Immune Defic Syndr; 2001 Aug; 27(4):350-64. PubMed ID: 11468423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A randomized clinical trial to compare the effectiveness of indinavir, ritonavir and saquinavir].
    Teira R; Cámara MM; Escobar A; Muñoz P; López de Munain J; Santamaría JM
    Med Clin (Barc); 2003 Oct; 121(14):532-4. PubMed ID: 14599408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study.
    Mallolas J; Blanco J; Labarga P; Vergara A; Ocampo A; Sarasa M; Arnedo M; López-Púa Y; García J; Juega J; Guelar A; Terrón A; Dalmau D; García I; Zárraga M; Martínez E; Carné X; Pumarola T; Escayola R; Gatell J
    HIV Med; 2007 May; 8(4):226-33. PubMed ID: 17461850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of two modalities of triple HIV therapy: probable superiority of indinavir.
    Eiros Bouza JM; Ortega M; Ortiz de Lejarazu R; Blanco R; Bachiller P; de Luis DA
    Int J Antimicrob Agents; 2004 Mar; 23(3):304-6. PubMed ID: 15164974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients.
    de Mendoza C; Valer L; Ribera E; Barreiro P; Martín-Carbonero L; Ramirez G; Soriano V
    HIV Clin Trials; 2006; 7(4):163-71. PubMed ID: 17065028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lopinavir protein binding in vivo through the 12-hour dosing interval.
    Boffito M; Hoggard PG; Lindup WE; Bonora S; Sinicco A; Khoo SH; Di Perri G; Back DJ
    Ther Drug Monit; 2004 Feb; 26(1):35-9. PubMed ID: 14749547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients.
    Ford J; Boffito M; Wildfire A; Hill A; Back D; Khoo S; Nelson M; Moyle G; Gazzard B; Pozniak A
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2388-93. PubMed ID: 15215085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
    HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.